- 英文名称
- AMG-337
- 分子式
- C23H22FN7O3
- 分子量
- 463.46
- 中文别名
- (R)-6-(1-(8-氟-6-(1-甲基-1H-吡唑-4-基)-[1,2,4]三唑并[4,3-a]吡啶-3-基)乙基)-3-(2-甲氧基乙氧基)-1,6-萘啶-5(6H)-酮; AMG-337游离态; 化合物AMG337; MET激酶抑制剂AMG-337; 6-[(1R)-1-[8-氟-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-a]吡啶-3-基]乙基]-3-(2-甲氧基乙氧基)-1,6-萘啶-5(6H)-酮; 抑制剂AMG-337; amg-337; AMG 337; AMG337; 6-{(1R)-1-[8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one; 1,6-Naphthyridin-5(6H)-one, 6-[(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-; 6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one; 6-((1R)-1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one; 6-[(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-5,6-dihydro-1,6-naphthyridin-5-one; 6-((1R)-1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-5,6-dihydro-1,6-naphthyridin-5-one; 6-((1R)-1-(8-fluoro-6-(1-methylpyrazol-4-yl)-(1,2,4)triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one; C-MET INHIBITOR AMG 337; 6-[(1~{r})-1-[8-Fluoranyl-6-(1-Methylpyrazol-4-Yl)-[1,2,4]triazolo[4,3-A]pyridin-3-Yl]ethyl]-3-(2-Methoxyethoxy)-1,6-Naphthyridin-5-One
- 用途
- 化学合成；作为口服的、ATP竞争性的、高度选择性Met (c-Met) 受体抑制剂，IC50为1 nM，用于抑制野生型MET及部分MET突变体的酶活性，抑制PC3细胞中HGF诱导的MET磷酸化，抑制MET依赖性癌细胞增殖，在体内实验中能抑制大于90% Gab-1的磷酸化，耐受性良好，具有检验MET作用的临床属性。
